https://doi.org/10.55788/47c409cb
Administration of modified immune cells prior to kidney transplantation resulted in specific immunosuppression against the allogeneic donor and a significant increase in Breg [2]. Dr Matthias Schaier (Heidelberg University, Germany) explained that he and his team investigated how this approach affects the clinical course of treated patients. “We compared the clinical outcomes of 10 patients from a phase 1 clinical trial who had received modified immune blood cell infusions before kidney transplantation to the results of 15 matched standard-risk recipients. Follow-up was until year 5 after surgery.” The 10 patients who received modified immune blood cell infusions showed an excellent clinical course with stable kidney graft function and showed no donor-specific human leukocyte antigen antibodies or acute rejections during follow-up. In the other group, 1 of the patients died, and 5 developed donor-specific human leukocyte antigen antibodies. Opportunistic infections were reported more frequently in the control group than in those receiving modified immune blood cell infusion. Dr Schaier mentioned that based on these findings, modified donor blood cells may be a useful tool for the targeted induction of tolerogenic Breg. “Also, a phase 2 study is underway to test the hypothesis that modified donor blood cell infusions lead to an operational tolerance-like phenotype [1].”
- Schaier M, et al. Five-Year Follow-Up of a Phase 1 Trial of Donor-Derived Modified Immune Cell Infusion in Kidney Transplantation. SA-OR47, ASN Kidney Week 2022, 3–6 Nov.
- Morath C, et al. J Clin Invest 2020;130:2364–2376.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Wearable serum potassium-monitoring device serves haemodialysis patients well Next Article
Balanced crystalloid solution better for deceased donor kidney transplantations »
« Wearable serum potassium-monitoring device serves haemodialysis patients well Next Article
Balanced crystalloid solution better for deceased donor kidney transplantations »
Table of Contents: ASN 2022
Featured articles
Chronic Kidney Disease
VALOR-CKD trial did not show any benefits for veverimer
EMPA-KIDNEY: empagliflozin slashes kidney disease progression or CV death
Combining UACR and GFR improves prediction of drug effect in CKD phase 2 trials
Dapagliflozin reduces number of hospitalisations in patients with CKD
Novel MSC therapy appears safe and effective in preventing decline in eGFR
Dapagliflozin improves anaemia in patients with CKD with or without T2D
Kidney Transplantation and Dialysis
Balanced crystalloid solution better for deceased donor kidney transplantations
Modified donor blood cells seem a promising option in kidney transplant recipients
Cooler dialysate does not offer any clinical benefits
Antiviral effect of MAU868 against BK virus prompts further research
General Nephrology
Medication-targeted alerts for the risk of AKI
Coaching with a DASH diet improves albuminuria
Cemdisiran shows promise in IgA nephropathy
Long-term nephroprotective effects of sparsentan in FSGS
Encaleret normalises mineral homeostasis in patients with ADH1
Adding voclosporin to MMF and steroids results in long-term higher CRR in severe lupus nephritis
Selonsertib poses risk of AKI in patients with DKD
Significantly higher risk of overcorrection in hyponatraemic patients with standard bolus infusion
Lowering blood pressure intervention favourable for CV outcomes
Related Articles
![](https://conferences.medicom-publishers.com/wp-content/uploads/2024/02/Rare-Diseases-Day_key-stats-square-eng-3-1024x1024.png)
February 26, 2024
Join the conversation on Rare Disease Awareness Day
October 20, 2023
Analysing the Link Between Psoriasis and Chronic Kidney Disease
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com